StockData
CytomX Therapeutics, Inc. logo

CytomX Therapeutics, Inc. (CTMX) stock

CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$1.94−0.05 (-2.27%)

Close on Nov 17, 2026Market cap $422.73MP/E –Yield –

CytomX Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

CytomX Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$82.41M. For fiscal 2025 it was -$75.59M. The highest annual figure on record is $170.37M in fiscal 2017.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$75.59M–
FY2024Dec 31, 2024-$86.23M–
FY2023Dec 31, 2023-$56.04M–
FY2022Dec 31, 2022-$110.79M–
FY2021Dec 31, 2021-$119.03M-2363.4%
FY2020Dec 31, 2020$5.26M–
FY2019Dec 31, 2019-$140.48M–
FY2018Dec 31, 2018-$75.52M-144.3%
FY2017Dec 31, 2017$170.37M–
FY2016Dec 31, 2016-$2.03M–
FY2015Dec 31, 2015-$27.42M-186.2%
FY2014Dec 31, 2014$31.80M–
FY2013Dec 31, 2013-$8.01M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$18.07M–
Q1 FY2026Mar 31, 2026-$25.55M–
Q4 FY2025Dec 31, 2025-$23.24M–
Q3 FY2025Sep 30, 2025-$15.55M–
Q2 FY2025Jun 30, 2025-$15.75M–
Q1 FY2025Mar 31, 2025-$21.04M–
Q4 FY2024Dec 31, 2024-$19.91M–
Q3 FY2024Sep 30, 2024-$20.73M–
Q2 FY2024Jun 30, 2024-$19.55M–
Q1 FY2024Mar 31, 2024-$26.05M-378.6%
Q4 FY2023Dec 31, 2023-$21.96M–
Q3 FY2023Sep 30, 2023-$18.24M–
Q2 FY2023Jun 30, 2023-$25.18M–
Q1 FY2023Mar 31, 2023$9.35M–
Q4 FY2022Dec 31, 2022-$1.39M–
Q3 FY2022Sep 30, 2022-$33.85M–
Q2 FY2022Jun 30, 2022-$34.24M–
Q1 FY2022Mar 31, 2022-$41.31M–
Q4 FY2021Dec 31, 2021-$31.19M–
Q3 FY2021Sep 30, 2021-$29.70M–
Q2 FY2021Jun 30, 2021-$28.20M-129.0%
Q1 FY2021Mar 31, 2021-$29.94M–
Q4 FY2020Dec 31, 2020-$17.43M–
Q3 FY2020Sep 30, 2020-$24.68M–
Q2 FY2020Jun 30, 2020$97.10M–
Q1 FY2020Mar 31, 2020-$49.74M–
Q4 FY2019Dec 31, 2019-$29.48M–
Q3 FY2019Sep 30, 2019-$23.32M–
Q2 FY2019Jun 30, 2019-$48.65M–
Q1 FY2019Mar 31, 2019-$39.03M–
Q4 FY2018Dec 31, 2018-$28.74M-230.6%
Q3 FY2018Sep 30, 2018-$5.55M–
Q2 FY2018Jun 30, 2018-$26.62M-115.4%
Q1 FY2018Mar 31, 2018-$14.61M–
Q4 FY2017Dec 31, 2017$22.00M+1036.5%
Q3 FY2017Sep 30, 2017-$5.74M–
Q2 FY2017Jun 30, 2017$173.20M–
Q1 FY2017Mar 31, 2017-$19.09M–
Q4 FY2016Dec 31, 2016$1.94M–
Q3 FY2016Sep 30, 2016-$14.18M–

More CytomX Therapeutics figures

See a number that looks wrong?